Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ 49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2019
Price :
$35
*
At a glance
- Drugs RV 568 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.